Global In Vitro Diagnostics IVD Quality Control Market Size By Type (Quality Controls, Data Management), By Application (Clinical Chemistry, Immunochemistry), By Region, And Segment Forecasts, 2023 to...

The Global In Vitro Diagnostics (IVD) Quality Control Market was valued at USD 1.3 billion in 2023 and is projected to reach USD 2.2 billion by 2031, growing at a CAGR of 6.8% during the forecast period from 2023 to 2031. The market is witnessing significant growth due to the rising demand for reliable and accurate diagnostic results, the increasing prevalence of chronic and infectious diseases, and the expanding use of IVD tests in clinical laboratories. Quality control (QC) materials ensure the validity of test results, making them indispensable in clinical diagnostics.

Drivers:

1. Growing Emphasis on Diagnostic Accuracy:

With healthcare systems focusing on early and accurate disease diagnosis, the demand for robust IVD quality control systems has surged. QC products help monitor analytical performance, reduce errors, and ensure consistency.

2. Expansion of Clinical Laboratory Testing:

As the global healthcare infrastructure expands, especially in developing nations, there’s a growing number of laboratories offering diagnostic testing services. This expansion drives the need for reliable quality control measures.

3. Increasing Prevalence of Chronic and Infectious Diseases:

The surge in diseases such as diabetes, cancer, HIV, and COVID-19 has led to increased diagnostic testing volumes. With this rise, the demand for IVD QC products that validate and ensure testing accuracy also rises.

Restraints:

1. High Cost of Quality Control Materials:

The recurring cost of QC materials, especially third-party controls for a wide range of analytes, can be a financial burden for smaller laboratories and facilities with budget constraints.

2. Regulatory and Compliance Complexity:

Regulatory compliance varies across regions and often requires significant time and resource investment, making market entry and expansion challenging for companies.

Opportunity:

1. Technological Advancements in QC Products:

Manufacturers are developing multi-analyte, consolidated quality control materials and software-based solutions that offer real-time monitoring, which enhances efficiency and reduces manual intervention.

2. Market Penetration in Emerging Economies:

Rapid growth in the healthcare sector across Asia-Pacific, Latin America, and the Middle East presents untapped opportunities for IVD QC product manufacturers due to increasing healthcare investments and diagnostic awareness.

Market by System Type Insights:

The third-party control segment dominated the market in 2023, driven by its advantages over manufacturer-provided controls, including lot-to-lot consistency and applicability across multiple platforms. These controls are preferred in accreditation-compliant laboratories for unbiased performance monitoring.

Market by End-Use Insights:

In 2023, the clinical laboratories segment held the largest share of the market. These facilities extensively use IVD tests for disease screening, monitoring, and therapeutic decisions. The growing test volumes and stringent quality requirements make QC implementation critical in this segment.

Market by Regional Insights:

North America led the market in 2023 due to well-established healthcare systems, stringent regulatory frameworks, and a strong presence of leading QC solution providers. Asia-Pacific is projected to witness the highest growth during the forecast period, propelled by rising healthcare investments, diagnostic adoption, and growing disease burden in countries like China and India.

Competitive Scenario:

Key players in the global IVD Quality Control market include Bio-Rad Laboratories, Thermo Fisher Scientific, Roche Diagnostics, Siemens Healthineers, Abbott Laboratories, Randox Laboratories, LGC Limited, and Streck Inc. These companies are emphasizing innovation, expanding their product portfolios, and adopting strategies like acquisitions and partnerships to strengthen their market positions.

Scope of Work – Global In Vitro Diagnostics (IVD) Quality Control Market

Report Metric Details

Market Size (2023) USD 1.3 billion

Projected Market Size (2031) USD 2.2 billion

CAGR (2023–2031) 6.8%

Market Segments By System Type (Third-party Controls, Instrument-specific Controls), By End-use (Clinical Laboratories, Hospitals, Academic Institutions), By Region

Growth Drivers Demand for diagnostic accuracy, rising chronic disease burden, expansion of laboratory testing

Opportunities Emerging markets, consolidation of QC materials, real-time monitoring tools

Key Market Developments:

2023: Bio-Rad Laboratories launched an integrated digital quality control platform, enhancing real-time data monitoring and compliance tracking in laboratories.

2023: Randox Laboratories introduced multi-analyte QC kits for infectious disease testing to support COVID-19 and influenza diagnostics.

2024: Abbott Laboratories partnered with leading diagnostic labs in Asia to expand access to third-party QC solutions, addressing local regulatory requirements.

FAQs:

1. What is the current market size of the Global In Vitro Diagnostics (IVD) Quality Control Market?

The market size in 2023 is USD 1.3 billion.

2. What is the major growth driver of the Global In Vitro Diagnostics (IVD) Quality Control Market?

The rising demand for diagnostic accuracy and the growing prevalence of chronic and infectious diseases.

3. Which is the largest region during the forecast period in the Global In Vitro Diagnostics (IVD) Quality Control Market?

North America holds the largest market share.

4. Which segment accounted for the largest market share in Global In Vitro Diagnostics (IVD) Quality Control Market?

The third-party control segment led the market in 2023.

5. Who are the key market players in the Global In Vitro Diagnostics (IVD) Quality Control Market?

Bio-Rad Laboratories, Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Randox Laboratories.